{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-010777","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.021739+00:00","generated_at":"2026-05-25T05:56:26.207505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025","bullets":["Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.","Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.","R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.","Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.","VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-010777","json":"https://secwatch.observer/filing/0001628280-25-010777.json","markdown":"https://secwatch.observer/filing/0001628280-25-010777.md","text":"https://secwatch.observer/filing/0001628280-25-010777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/0001628280-25-010777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/mnlo-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:56:26.207505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}